Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MCRB countdown to tomorrow's PDUFA. Have you loaded?
https://stockcharts.com/h-sc/ui?s=MCRB
MG
MCRB Wednesday PDUFA
While we wait..
Weekend Music
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171755545
MCRB In today for PDUFA next week.
Have a great weekend, all!
MG
No rebuttal? Is this market even worldwide? Or am I on some fake market for just my pc?
I don't know why pharma wouldn't short this POS, if they cure recurrent c. diff it's no longer recurrent and so you aren't selling anything. Doesn't seem like the business model works at all.
It's like sellin' food with vitamins still in it when your competitors did a manual extraction and started selling a separate line of vitamin pills.
It's recurrent for a reason!
MCRB is a great $$$$$ opportunity.
Current shelf placement closes Monday, and generates over $200M .
Plus we have a huge new life saving drug coming to marketplace.
* * $MCRB Video Chart 08-13-2020 * *
Link to Video - click here to watch the technical chart video
* * $MCRB Video Chart 08-10-2020 * *
Link to Video - click here to watch the technical chart video
This is HUGE... I am an NP so I know!!
73k CDI episodes of 2+ recurrences/year in US as studied in current study. Another 100k/year primary recurrence cases being studied in open label extension trial. Will SER-109 eventually be studied and used for the other 439k/year CDI patients in US to prevent any recurrences?
MCRB discovers immortality = stock quadruples lol
Good grief chief $$$$$$$$$$$$
MCRB @ 19.39 up 317% >
16.95 up 275% in PM. > FDA phase III news!
Seres Therapeutics Phase 3 SER-109 Study Meets Main Endpoint >MCRB
7:06 am ET August 10, 2020 (Dow Jones) Print
By Colin Kellaher
Seres Therapeutics Inc. on Monday said a pivotal phase 3 study of its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection met its primary endpoint.
The Cambridge, Mass., developer of biological drugs said SER-109 showed a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared with placebo, adding that the drug was well tolerated, with a safety profile comparable to placebo.
Seres also said the study's efficacy results exceeded the U.S. Food and Drug Administration's statistical threshold that could allow the single study to fulfill efficacy requirements for a biologics license application, and the company said it plans to meet with the agency to discuss filing for product approval as soon as possible.
C. difficile, an antibiotic-resistant bacterium, is a leading cause of hospital-acquired infection in the U.S.
Shares of Seres, which closed Friday at $4.64, more than tripled to $14.20 in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
* * $MCRB Video Chart 06-29-2019 * *
Link to Video - click here to watch the technical chart video
* * $MCRB Video Chart 06-14-2019 * *
Link to Video - click here to watch the technical chart video
* * $MCRB Video Chart 03-11-2019 * *
Link to Video - click here to watch the technical chart video
10.71 BOL BAND ..SHOULD BOUNCE BACK DOWN FROM THAT...PLUS RSI HIGH = SELL
Marino, picking up nickels in front of a bulldozer...
Hi everyone! Been in since $9.28, love this stock, we should be seeing higher lows for the foreseeable future, good luck everyone!
Have u checked EARS and CERU
Good my friend
Instill have 700 shares and my target is 30 cents away. Been a good one since five trading days....$8.92 to $12
Congrats for hitting your target. I'm thinking possible shorts when the rally runs out of steam. Too busy these days. Have yet to read its ER transcript. Have you listened to it or read it? What're the key things. Would be great to know before I find time to read it. Thanks.
Lol. $1.30 more and I'll hit my one week target. I was looking at next week but it may come anytime now.
Hard to imagine where these idiots and mm shorts are getting the shares to sell. But my target is unchanged at $12.
$12. It was headed straight there like an arrow. Should I have gotten more T $8.90s....you bet!!! But you have to have some heart to look beyond the shorting game here and see the opportunity. It takes some brain work.....
With what I heard on the cc.....you will get stabilization here in the $15 range until new update regard 109. It may see $12 as early as next week.
So far I've bot 3200 between$8.80 and $8.91. Played out well...I was worried I may chase it above $10. Now it is chasing me....lol
Got some in-the-money to play any positive news release which I believe is very likely.
What's your average
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
292
|
Created
|
06/25/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |